About
Schizophrenia Treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Team (13)
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
1,715
By Phase
PHASE4: 2PHASE2: 1PHASE1: 2
By Status
COMPLETED: 4NOT_YET_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT06129526Collaborator
Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
PHASE4Not yet recruiting
450 participants
Started: Dec 31, 2023 · Completed: Dec 31, 2024
NCT06179108Lead Sponsor
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
PHASE2Completed
359 participants
Started: Nov 29, 2023 · Completed: Dec 4, 2024
NCT04588129Lead Sponsor
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
PHASE1Completed
16 participants
Started: Jan 5, 2021 · Completed: Nov 15, 2021
NCT04187560Lead Sponsor
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
PHASE1Completed
64 participants
Started: Jan 22, 2020 · Completed: Nov 9, 2020
NCT02983214Collaborator
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
PHASE4Completed
826 participants
Started: Nov 30, 2016 · Completed: Oct 31, 2019
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...